suki the dog
22 Sep 2016
Very positive 22 September 2016 Avacta Group plc("Avacta" or "the Group" or "the Company"
Positive results from first preclinical in-vivo studies of Affimer therapeutics Affimer PD-L1 inhibitor significantly reduces tumour growth in mouse model · Good pharmacokinetic properties observed· Affimer molecules well tolerated at all dosing levels· No adverse effects observed· Confirms the potential of the Affimer technology as a therapeutic platform Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules. The results meaningfully de-risk the development of the technology as a therapeutic platform; demonstrating that Affimer molecules possess good drug-like properties in terms of efficacy, serum half-life and tolerability. Two parallel in-vivo pre-clinical studies have been completed. The first, a pharmacokinetics study looking at both human and mouse PD-L1 Affimer inhibitors1 engineered as Fc fusions2, showed that Affimer molecules have good in-vivo serum half-lives and are well tolerated at the clinically relevant doses used in the study. The second was an efficacy study using a mouse PD-L1 specific Affimer molecule in a syngeneic tumour model3. In this study the Affimer PD-L1 inhibitor produced a statistically significant reduction in tumour growth demonstrating the bioavailability and functionality of the Affimer molecule in tumours in-vivo. No adverse effects were observed. Alastair Smith, Avacta Group Chief Executive commented: "These results demonstrate that Affimer molecules possess good -in-vivo drug-like properties in terms of efficacy, serum half-life and tolerability which is a hugely important milestone in the development and de-risking of the technology as a therapeutic platform. From the initial screening process for the Affimer binders we have been able to rapidly progress to evaluating them in in-vivo models, highlighting another major advantage of the technology. We are very encouraged by these initial positive results and will continue to focus on developing both our internal and partnered therapeutic programs towards clinical validation."
suki the dog
12 Sep 2016
Re: Moderna Yes that's it Sold out of hurricane energy done really well with it Think AVACTA could be nextTake car
mol42
12 Sep 2016
Re: Moderna this would be it from london stock exchange10:35:39 12-Sep-2016 101.50 24,624 24,993.36 Ordinary Trade - delayed publicationas shows here around 13.35though haven't added myself recently overweight on aim shares at moment! albeit waiting to sell one or two on the proverbial news.... bw Sukimol
suki the dog
12 Sep 2016
Re: Moderna I picked up another £25,000 this morning, bringing my total to 42,000 shar
mol42
12 Sep 2016
Re: Moderna just doodling in general re avacta this evening[link] further fund raise!and zika virus to boot news!the risk appetite over there far outweighs UK marketanyway lets hope some of that $1.4b makes its further way to us!mol
BigSwede
12 Jan 2016
After Pure Wafer did their consolidation the price really took off - here's hoping for a repeat performance!
BuyBAO
19 May 2015
1.2 paid
BuyBAO
19 May 2015
1.19 paid even
BuyBAO
19 May 2015
1.9 paid
BuyBAO
19 May 2015
Will get interesting when 1.2 goes
BuyBAO
19 May 2015
Steadying buying
BuyBAO
18 May 2015
Interesting one and worth a punt 
sandgrounder
18 May 2015
CEO says "It is a transformational deal for Avacta and Affimers"
